PMC:7321036 / 45957-46095 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T368","span":{"begin":63,"end":71},"obj":"Body_part"},{"id":"T369","span":{"begin":103,"end":107},"obj":"Body_part"}],"attributes":[{"id":"A368","pred":"fma_id","subj":"T368","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A369","pred":"fma_id","subj":"T369","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T561","span":{"begin":60,"end":62},"obj":"http://purl.obolibrary.org/obo/CLO_0008192"},{"id":"T562","span":{"begin":103,"end":107},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T316","span":{"begin":39,"end":43},"obj":"Chemical"},{"id":"T317","span":{"begin":60,"end":62},"obj":"Chemical"}],"attributes":[{"id":"A316","pred":"chebi_id","subj":"T316","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A317","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A318","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_53793"},{"id":"A319","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_73425"}],"text":"Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted."}

{"project":"LitCovid-sentences","denotations":[{"id":"T304","span":{"begin":0,"end":138},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted."}